Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571

Oncogene volume 21, pages 5868–5876 (2002)Cite this article

Abstract

BCR/ABL fusion tyrosine kinase is responsible for the initiation and maintenance of the Philadelphia chromosome (Ph1)-positive chronic myelogenous leukemia (CML) and a cohort of acute lymphocytic leukemias (ALL). STI571 (Gleevec), a novel anti-leukemia drug targeting BCR/ABL kinase can induce remissions of the Ph1-positive leukemias. STI571 was recently combined with the standard cytostatic drugs to achieve better therapeutic results and to overcome emerging drug resistance mechanisms. We decided to search for a more specific partner compound for STI571. Our previous studies showed that a signaling protein phosphatidylinositol-3 kinase (PI-3k) is essential for the growth of CML cells, but not of normal hematopoietic cells (Blood, 86:726,1995). Therefore the anti- Ph1-leukemia effect of the combination of BCR/ABL kinase inhibitor STI571 and PI-3k inhibitor wortmannin (WT) or LY294002 (LY) was tested. We showed that STI571+WT exerted a synergistic effect against the Ph1-positive cell lines, but did not affect the growth of Ph1-negative cell line. Moreover, the combinations of STI571+WT or STI571+LY were effective in the inhibition of clonogenic growth of CML-chronic phase and CML-blast crisis patient cells, while sparing normal bone marrow cells. Single colony RT–PCR assay showed that colonies arising from the mixture of CML cells and normal bone marrow cells after treatment with STI571+WT were selectively depleted of BCR/ABL-positive cells. Biochemical analysis of the CML cells after the treatment revealed that combination of STI571+WT caused a more pronounced activation of caspase-3 and induced massive apoptosis, in comparison to STI571 and WT alone. In conclusion, combination of STI571+WT or STI571+LY may represent a novel approach against the Ph1-positive leukemias.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G . 2000 N. Engl. J. Med. 342: 998–1006

  • Canitrot Y, Lautier D, Laurent G, Frechet M, Ahmed A, Turhan AG, Salles B, Cazaux C, Hoffmann JS . 1999 Oncogene 18: 2676–2680

  • Carlesso N, Frank DA, Griffin JD . 1996 J. Exp. Med. 183: 811–820

  • Carpenter CL, Cantley LC . 1996 Curr. Opin. Cell. Biol. 8: 153–158

  • Chai SK, Nichols GL, Rothman P . 1997 J. Immunol. 159: 4720–4728

  • Clift RA, Storb R . 1996 Bone Marrow Transplant 17: Suppl S1–S3

  • Copelan EA, McGuire EA . 1995 Blood 85: 1151–1168

  • de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L . 1999 Blood 94: 1108–1112

  • Dhut S, Chaplin T, Young BD . 1990 Leukemia 4: 745–750

  • Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M . 2001 Blood 97: 2846–2853

  • Druker BJ, Lydon NB . 2000 J. Clin. Invest. 105: 3–7

  • Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M . 2001a N. Engl. J. Med. 344: 1038–1042

  • Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . 2001b N. Engl. J. Med. 344: 1031–1037

  • Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB . 1996 Nat. Med. 2: 561–566

  • Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM . 1999 N. Engl. J. Med. 341: 164–172

  • Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN . 2000 Blood 96: 2246–2253

  • Fry MJ, Waterfield MD . 1993 Philos. Trans. R. Soc. Lond. B. Biol. Sci. 340: 337–344

  • Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, Greinix H, Mannhalter C, Haas OA, Lechner, Lioh T . 1995 Blood 86: 2371–2378

  • Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D'Incalci M . 2000 J. Natl. Cancer. Inst. 92: 1641–1650

  • Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD . 2000 J. Biol. Chem. 275: 39223–39230

  • Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON . 1995 Cell 82: 981–988

  • Gordon MY, Dazzi F, Marley SB, Lewis JL, Nguyen D, Grand FH, Davidson RJ, Goldman JM . 1999 Leukemia 13: Suppl S65–S71

  • Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL . 2001 Science 293: 876–880

  • Gratwohl A, Hermans J . 1996 Bone Marrow Transplant 17: Suppl S7–S9

  • Haseyama Y, Sawada K, Oda A, Koizumi K, Takano H, Tarumi T, Nishio M, Handa M, Ikeda Y, Koike T . 1999 Blood 94: 1568–1577

  • Hawkins PT, Welch H, McGregor A, Eguinoa A, Gobert S, Krugmann S, Anderson K, Stokoe D, Stephens L . 1997 Biochem. Soc. Trans. 25: 1147–1151

  • Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP . 2002 Blood 99: 1860–1862

  • Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL . 2000 J. Exp. Med. 191: 977–984

  • Ilaria Jr RL, Hawley RG, Van Etten RA . 1999 Blood 93: 4154–4166

  • Ilaria Jr RL, Van Etten RA . 1996 J. Biol. Chem. 271: 31704–31710

  • Kang CD, Do IR, Kim KW, Ahn BK, Kim SH, Chung BS, Jhun BH, Yoo MA . 1999 Exp. Mol. Med. 31: 76–82

  • Kang CD, Yoo SD, Hwang BW, Kim KW, Kim DW, Kim CM, Kim SH, Chung BS . 2000 Leuk. Res. 24: 527–534

  • Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y . 2001 Blood 97: 1999–2007

  • Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM . 2001 Blood 98: 1773–1781

  • Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD . 2001 Annu. Rev. Cell. Dev. Biol. 17: 615–675

  • Klucher KM, Lopez DV, Daley GQ . 1998 Blood 91: 3927–3934

  • Kolonics A, Apati A, Janossy J, Brozik A, Gati R, Schaefer A, Magocsi M . 2001 Cell Signal 13: 743–754

  • Kulik G, Weber MJ . 1998 Mol. Cell. Biol. 18: 6711–6718

  • le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C . 2000 Blood 95: 1758–1766

  • Lugo TG, Pendergast AM, Muller AJ, Witte ON . 1990 Science 247: 1079–1082

  • Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV . 2000 Blood 96: 1070–1079

  • Marley SB, Deininger MW, Davidson RJ, Goldman JM, Gordon MY . 2000 Exp. Hematol. 28: 551–557

  • Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL . 2000 Mol. Cell. Biol. 20: 1179–1186

  • Nguyen MH, Ho JM, Beattie BK, Barber DL . 2001 J. Biol. Chem. 276: 32704–32713

  • Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T . 1999 J. Exp. Med. 189: 1229–1242

  • Nielsen M, Svejgaard A, Skov S, Dobson P, Bendtzen K, Geisler C, Odum N . 1996 J. Immunol. 157: 5350–5358

  • Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML . 1993 Cell 75: 175–185

  • Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R . 1999 Mol. Cell. Biol. 19: 7203–7215

  • Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T . 1994 EMBO J. 13: 764–773

  • Raitano AB, Whang YE, Sawyers CL . 1997 Biochim. Biophys. Acta 1333: F201–F216

  • Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M . 1999 Cancer 86: 2632–2641

  • Salloukh HF, Laneuville P . 2000 Leukemia 14: 1401–1404

  • Sattler M, Salgia R . 1997 Cytokine Growth Factor Rev. 8: 63–79

  • Sawyers CL . 1999 N. Engl. J. Med. 340: 1330–1340

  • Sawyers CL, McLaughlin J, Witte ON . 1995 J. Exp. Med. 181: 307–313

  • Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . 2000 Science 289: 1938–1942

  • Segouffin-Cariou C, Billaud M . 2000 J. Biol. Chem. 275: 3568–3576

  • Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD . 2000 Blood 95: 2118–2125

  • Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S . 1999 Blood 94: 1517–1536

  • Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B . 1997a EMBO J. 16: 6151–6161

  • Skorski T, Kanakaraj P, Ku DH, Nieborowska-Skorska M, Canaani E, Zon G, Perussia B, Calabretta B . 1994 J. Exp. Med. 179: 1855–1865

  • Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B . 1995a Blood 86: 726–736

  • Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szcyzlik C, Chen ST, Lange B, Calabretta B . 1993 J. Clin. Invest. 92: 194–202

  • Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B . 1995b J. Exp. Med. 182: 1645–1653

  • Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B . 1997b J. Natl. Cancer Inst. 89: 124–133

  • Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B . 1996 Blood 88: 1005–1012

  • Skorski T, Szczylik C, Ratajczak MZ, Malaguarnera L, Gewirtz AM, Calabretta B . 1992 J. Exp. Med. 175: 743–750

  • Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T . 2001 Cancer Res. 61: 2194–2199

  • Somwar R, Niu W, Kim DY, Sweeney G, Randhawa VK, Huang C, Ramlal T, Klip A . 2001 J. Biol. Chem. 276: 46079–46087

  • Stephens LR, Jackson TR, Hawkins PT . 1993 Biochim. Biophys. Acta 1179: 27–75

  • Sun X, Layton JE, Elefanty A, Lieschke GJ . 2001 Blood 97: 2008–2015

  • Talpaz M, Kantarjian H, McCredie K, Trujillo J, Keating M, Gutterman JU . 1987 Cancer 59: 664–667

  • Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN . 1998 Cell 93: 841–850

  • Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ . 2000 Blood 96: 3195–3199

  • Timokhina I, Kissel H, Stella G, Besmer P . 1998 EMBO J. 17: 6250–6262

  • Toker A, Cantley LC . 1997 Nature 387: 673–676

  • Topaly J, Zeller WJ, Fruehauf S . 2001 Leukemia 15: 342–347

  • Van Etten RA . 2001 Blood Cells Mol. Dis. 27: 201–205

  • Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC . 1991 Mol. Cell. Biol. 11: 1107–1113

  • von Bubnoff N, Schneller F, Peschel C, Duyster J . 2002 Lancet 359: 487–491

  • Weisberg E, Griffin JD . 2000 Blood 95: 3498–3505

  • Welham MJ, Duronio V, Sanghera JS, Pelech SL, Schrader JW . 1992 J. Immunol. 149: 1683–1693

  • Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R . 1993 J. Clin. Invest. 92: 1925–1939

  • Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB . 2001 Oncogene 20: 6188–6195

  • Yu C, Krystal G, Varticovski L, McKinstry R, Rahmani M, Dent P, Grant S . 2002 Cancer Res. 62: 188–199

Download references

Acknowledgements

This work was supported in part by NIH CA87300. T Skorski is a Scholar of the Leukemia and Lymphoma Society. A Slupianek is a recipient of the fellowship from Leukemia Research Foundation and was also supported by Elsa U Pardee grant. A Morrione was supported by the KO1 DK02896.

Author information

Authors and Affiliations

  1. Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, 19122, Pennsylvania, PA, USA

    Agata Klejman, Lori Rushen, Artur Slupianek & Tomasz Skorski

  2. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, 19107, Pennsylvania, PA, USA

    Andrea Morrione

Authors
  1. Agata Klejman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lori Rushen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Morrione
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Artur Slupianek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomasz Skorski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomasz Skorski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klejman, A., Rushen, L., Morrione, A. et al. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21, 5868–5876 (2002). https://doi.org/10.1038/sj.onc.1205724

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205724

Keywords

This article is cited by

Search

Advanced search

Quick links